TDMS Study 90004-06 Pathology Tables
NTP Experiment-Test: 90004-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC PROPYLENE GLYCOL MONO-T-BUTYL ETHER Date: 01/02/02
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 09:24:21
FINAL/MICE
Facility: Battelle Northwest
Chemical CAS #: 57018-52-7
Lock Date: 12/11/00
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 90004-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC PROPYLENE GLYCOL MONO-T-BUTYL ETHER Date: 01/02/02
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 09:24:21
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 75 PPM 300 PPM 1200 PPM
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50 50
Early Deaths
Moribund Sacrifice 8 10 6 4
Natural Death 3 3 2 6
Accidently Killed 1 1
Survivors
Terminal Sacrifice 39 36 41 38
Natural Death 1 1
Animals Examined Microscopically 50 50 50 49
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (40) (39) (43) (33)
Histiocytic Sarcoma 1 (2%)
Intestine Large, Colon (48) (49) (50) (48)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%)
Intestine Large, Rectum (48) (49) (50) (48)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Intestine Large, Cecum (49) (48) (49) (46)
Histiocytic Sarcoma 1 (2%)
Leiomyoma 1 (2%)
Intestine Small, Duodenum (49) (47) (50) (46)
Histiocytic Sarcoma 1 (2%)
Intestine Small, Jejunum (49) (48) (48) (47)
Carcinoma 1 (2%)
Intestine Small, Ileum (49) (48) (48) (45)
Carcinoma 1 (2%)
Sarcoma, Metastatic, Skin 1 (2%)
Liver (49) (50) (50) (49)
Cholangioma 1 (2%)
Hemangioma 1 (2%)
Hemangiosarcoma 2 (4%)
Hepatoblastoma 2 (4%)
Hepatocellular Carcinoma 4 (8%) 8 (16%) 6 (12%) 8 (16%)
Hepatocellular Carcinoma, Multiple 1 (2%) 2 (4%)
Hepatocellular Adenoma 8 (16%) 8 (16%) 7 (14%) 5 (10%)
Hepatocellular Adenoma, Multiple 6 (12%) 3 (6%) 32 (65%)
Hepatocholangiocarcinoma 1 (2%)
Page 2
NTP Experiment-Test: 90004-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC PROPYLENE GLYCOL MONO-T-BUTYL ETHER Date: 01/02/02
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 09:24:21
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 75 PPM 300 PPM 1200 PPM
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - cont
Histiocytic Sarcoma 1 (2%) 1 (2%) 1 (2%)
Mesentery (17) (21) (13) (2)
Hemangiosarcoma 1 (6%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (8%)
Pancreas (49) (50) (50) (48)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%)
Salivary Glands (50) (50) (50) (49)
Stomach, Forestomach (49) (50) (50) (48)
Histiocytic Sarcoma 1 (2%)
Squamous Cell Papilloma 1 (2%) 1 (2%)
Stomach, Glandular (49) (48) (50) (48)
Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (50) (50) (49)
Sarcoma, Metastatic, Uncertain Primary Site 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (49) (50) (50) (48)
Carcinoma 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
Adrenal Medulla (47) (49) (50) (48)
Pheochromocytoma Malignant 1 (2%)
Islets, Pancreatic (49) (50) (50) (48)
Adenoma 1 (2%)
Pituitary Gland (48) (49) (47) (46)
Pars Distalis, Adenoma 9 (19%) 11 (22%) 12 (26%) 8 (17%)
Pars Intermedia, Adenoma 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Peritoneum (1) (2)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (50%)
Histiocytic Sarcoma 1 (50%)
____________________________________________________________________________________________________________________________________
Page 3
NTP Experiment-Test: 90004-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC PROPYLENE GLYCOL MONO-T-BUTYL ETHER Date: 01/02/02
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 09:24:21
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 75 PPM 300 PPM 1200 PPM
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Ovary (50) (49) (49) (48)
Carcinoma 1 (2%)
Cystadenoma 2 (4%) 1 (2%) 3 (6%) 1 (2%)
Histiocytic Sarcoma 1 (2%)
Luteoma 2 (4%) 1 (2%) 1 (2%)
Uterus (50) (50) (50) (48)
Adenoma 1 (2%)
Hemangiosarcoma 2 (4%)
Histiocytic Sarcoma 1 (2%)
Leiomyoma 2 (4%)
Leiomyosarcoma 1 (2%)
Polyp Stromal 1 (2%) 1 (2%)
Sarcoma Stromal 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (49) (50) (50) (48)
Hemangiosarcoma 1 (2%)
Histiocytic Sarcoma 1 (2%)
Lymph Node (4) (8) (6) (2)
Lumbar, Hemangiosarcoma 1 (17%)
Lymph Node, Bronchial (45) (34) (44) (42)
Histiocytic Sarcoma 1 (2%)
Lymph Node, Mandibular (44) (45) (45) (34)
Histiocytic Sarcoma 1 (3%)
Lymph Node, Mesenteric (48) (48) (48) (48)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Lymph Node, Mediastinal (40) (41) (41) (31)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (3%) 1 (2%)
Spleen (49) (50) (50) (48)
Hemangiosarcoma 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%) 1 (2%)
Thymus (45) (45) (46) (42)
Sarcoma, Metastatic, Uncertain Primary Site 1 (2%)
____________________________________________________________________________________________________________________________________
Page 4
NTP Experiment-Test: 90004-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC PROPYLENE GLYCOL MONO-T-BUTYL ETHER Date: 01/02/02
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 09:24:21
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 75 PPM 300 PPM 1200 PPM
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (50) (50) (50) (49)
Subcutaneous Tissue, Hemangiosarcoma 1 (2%)
Subcutaneous Tissue, Mast Cell Tumor Benign 1 (2%)
Subcutaneous Tissue, Sarcoma 1 (2%) 7 (14%) 1 (2%) 2 (4%)
Subcutaneous Tissue, Sarcoma, Multiple 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
None
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (50) (50) (49)
Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Larynx (50) (50) (50) (48)
Lung (50) (50) (50) (49)
Alveolar/Bronchiolar Adenoma 2 (4%) 2 (4%) 2 (4%)
Alveolar/Bronchiolar Carcinoma 1 (2%) 3 (6%) 1 (2%)
Alveolar/Bronchiolar Carcinoma, Multiple 1 (2%)
Carcinoma, Metastatic, Harderian Gland 1 (2%) 2 (4%)
Carcinoma, Metastatic, Ovary 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%) 4 (8%) 2 (4%) 3 (6%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%) 1 (2%)
Sarcoma, Metastatic, Skin 1 (2%)
Sarcoma, Metastatic, Uncertain Primary Site 1 (2%)
Nose (50) (50) (49) (49)
Carcinoma, Metastatic, Harderian Gland 1 (2%)
Pleura (1) (1)
Sarcoma, Metastatic, Uncertain Primary Site 1 (100%)
____________________________________________________________________________________________________________________________________
Page 5
NTP Experiment-Test: 90004-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC PROPYLENE GLYCOL MONO-T-BUTYL ETHER Date: 01/02/02
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 09:24:21
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 75 PPM 300 PPM 1200 PPM
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Eye (50) (50) (50) (48)
Carcinoma, Metastatic, Harderian Gland 1 (2%) 1 (2%)
Harderian Gland (50) (50) (50) (49)
Adenoma 3 (6%) 4 (8%) 5 (10%) 3 (6%)
Carcinoma 2 (4%) 2 (4%)
Bilateral, Adenoma 1 (2%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (49) (50) (50) (48)
Histiocytic Sarcoma 1 (2%)
Urinary Bladder (50) (49) (50) (47)
Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50) *(49)
Histiocytic Sarcoma 1 (2%) 1 (2%) 1 (2%)
Lymphoma Malignant 13 (26%) 15 (30%) 10 (20%) 7 (14%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 6
NTP Experiment-Test: 90004-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC PROPYLENE GLYCOL MONO-T-BUTYL ETHER Date: 01/02/02
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 09:24:21
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 75 PPM 300 PPM 1200 PPM
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 37 39 36 47
Total Primary Neoplasms 58 72 62 82
Total Animals with Benign Neoplasms 25 24 28 39
Total Benign Neoplasms 34 29 38 55
Total Animals with Malignant Neoplasms 23 30 20 22
Total Malignant Neoplasms 24 43 24 27
Total Animals with Metastatic Neoplasms 1 8 5 5
Total Metastatic Neoplasm 1 11 14 6
Total Animals with Malignant Neoplasms 1
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 7
NTP Experiment-Test: 90004-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC PROPYLENE GLYCOL MONO-T-BUTYL ETHER Date: 01/02/02
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 09:24:21
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 75 PPM 300 PPM 1200 PPM
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50 50
Early Deaths
Natural Death 11 4 4 5
Moribund Sacrifice 4 6 6 8
Survivors
Terminal Sacrifice 35 40 40 37
Animals Examined Microscopically 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (38) (41) (39) (40)
Sarcoma, Metastatic, Mesentery 1 (3%)
Intestine Large, Cecum (43) (47) (48) (48)
Carcinoma, Metastatic, Intestine Small,
Jejunum 1 (2%)
Polyp Adenomatous 1 (2%)
Intestine Small, Duodenum (43) (48) (47) (44)
Polyp Adenomatous 2 (4%) 1 (2%)
Intestine Small, Jejunum (42) (47) (47) (45)
Carcinoma 2 (5%) 1 (2%) 1 (2%) 1 (2%)
Polyp Adenomatous 1 (2%) 1 (2%) 1 (2%)
Intestine Small, Ileum (43) (47) (46) (46)
Carcinoma 1 (2%)
Liver (50) (49) (50) (50)
Hemangiosarcoma 2 (4%) 1 (2%) 1 (2%)
Hepatoblastoma 1 (2%) 5 (10%)
Hepatocellular Carcinoma 8 (16%) 7 (14%) 11 (22%) 9 (18%)
Hepatocellular Carcinoma, Multiple 1 (2%) 1 (2%) 2 (4%) 2 (4%)
Hepatocellular Adenoma 15 (30%) 16 (33%) 14 (28%) 13 (26%)
Hepatocellular Adenoma, Multiple 3 (6%) 7 (14%) 12 (24%) 23 (46%)
Histiocytic Sarcoma 1 (2%)
Osteosarcoma, Metastatic, Uncertain Primary
Site 1 (2%)
Plasma Cell Tumor Malignant, Metastatic,
Uncertain Primary Site 1 (2%)
Sarcoma, Metastatic, Mesentery 1 (2%)
Mesentery (14) (16) (13) (11)
Carcinoma, Metastatic, Intestine Small,
Jejunum 1 (7%)
Page 8
NTP Experiment-Test: 90004-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC PROPYLENE GLYCOL MONO-T-BUTYL ETHER Date: 01/02/02
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 09:24:21
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 75 PPM 300 PPM 1200 PPM
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - cont
Hemangiosarcoma 2 (13%)
Osteosarcoma, Metastatic, Uncertain Primary
Site 1 (7%)
Sarcoma 1 (8%)
Pancreas (48) (49) (50) (50)
Osteosarcoma, Metastatic, Uncertain Primary
Site 1 (2%)
Plasma Cell Tumor Malignant, Metastatic,
Uncertain Primary Site 1 (2%)
Sarcoma, Metastatic, Mesentery 1 (2%)
Salivary Glands (50) (50) (50) (50)
Stomach, Forestomach (48) (49) (50) (50)
Carcinoma, Metastatic, Intestine Small,
Jejunum 1 (2%)
Mast Cell Tumor Malignant, Metastatic, Bone
Marrow 1 (2%)
Epithelium, Squamous Cell Carcinoma 1 (2%)
Epithelium, Squamous Cell Papilloma 1 (2%)
Stomach, Glandular (46) (48) (50) (48)
Mast Cell Tumor Malignant, Metastatic, Bone
Marrow 1 (2%)
Sarcoma, Metastatic, Mesentery 1 (2%)
Tongue (1)
Squamous Cell Papilloma 1 (100%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (50) (50) (50)
Carcinoma, Metastatic, Intestine Small,
Jejunum 1 (2%)
Hemangiosarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (48) (49) (50) (50)
Adenoma 1 (2%)
Carcinoma 1 (2%)
Osteosarcoma, Metastatic, Uncertain Primary
Site 1 (2%)
Sarcoma, Metastatic, Mesentery 1 (2%)
Capsule, Adenoma 1 (2%)
Page 9
NTP Experiment-Test: 90004-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC PROPYLENE GLYCOL MONO-T-BUTYL ETHER Date: 01/02/02
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 09:24:21
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 75 PPM 300 PPM 1200 PPM
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM - cont
Subcapsular, Adenoma 1 (2%) 1 (2%) 1 (2%) 2 (4%)
Subcapsular, Carcinoma 1 (2%)
Adrenal Medulla (47) (49) (49) (49)
Pheochromocytoma Benign 1 (2%)
Islets, Pancreatic (48) (49) (50) (50)
Adenoma 2 (4%)
Thyroid Gland (48) (48) (49) (49)
Follicular Cell, Adenoma 1 (2%) 1 (2%)
Follicular Cell, Carcinoma 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Peritoneum (2)
Osteosarcoma, Metastatic, Uncertain Primary
Site 1 (50%)
Plasma Cell Tumor Malignant, Metastatic,
Uncertain Primary Site 1 (50%)
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (50) (50) (50) (50)
Prostate (49) (49) (47) (50)
Adenoma 1 (2%)
Seminal Vesicle (47) (49) (49) (49)
Adenoma 1 (2%)
Osteosarcoma, Metastatic, Uncertain Primary
Site 1 (2%)
Plasma Cell Tumor Malignant, Metastatic,
Uncertain Primary Site 1 (2%)
Sarcoma, Metastatic, Mesentery 1 (2%)
Testes (50) (50) (50) (50)
Carcinoma, Metastatic, Intestine Small,
Jejunum 1 (2%)
Hemangioma 1 (2%)
Interstitial Cell, Adenoma 2 (4%) 2 (4%)
____________________________________________________________________________________________________________________________________
Page 10
NTP Experiment-Test: 90004-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC PROPYLENE GLYCOL MONO-T-BUTYL ETHER Date: 01/02/02
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 09:24:21
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 75 PPM 300 PPM 1200 PPM
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (49) (49) (50) (50)
Mast Cell Tumor Malignant 1 (2%)
Lymph Node (2) (1) (4) (1)
Pancreatic, Sarcoma, Metastatic, Lymph Node,
Mesenteric 1 (25%)
Lymph Node, Bronchial (32) (36) (36) (35)
Osteosarcoma, Metastatic, Uncertain Primary
Site 1 (3%)
Plasma Cell Tumor Malignant, Metastatic,
Uncertain Primary Site 1 (3%)
Lymph Node, Mandibular (28) (38) (30) (25)
Lymph Node, Mesenteric (48) (49) (49) (50)
Plasma Cell Tumor Malignant, Metastatic,
Uncertain Primary Site 1 (2%)
Sarcoma, Metastatic, Mesentery 1 (2%)
Lymph Node, Mediastinal (39) (39) (43) (36)
Carcinoma, Metastatic, Intestine Small,
Jejunum 1 (3%)
Osteosarcoma, Metastatic, Uncertain Primary
Site 1 (3%)
Plasma Cell Tumor Malignant, Metastatic,
Uncertain Primary Site 1 (3%)
Spleen (48) (48) (50) (50)
Hemangiosarcoma 2 (4%) 1 (2%) 1 (2%)
Plasma Cell Tumor Malignant, Metastatic,
Uncertain Primary Site 1 (2%)
Thymus (40) (41) (39) (40)
Plasma Cell Tumor Malignant, Metastatic,
Uncertain Primary Site 1 (3%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (49) (50) (50) (50)
Subcutaneous Tissue, Fibrosarcoma 1 (2%)
Subcutaneous Tissue, Fibrous Histiocytoma 2 (4%) 2 (4%)
Subcutaneous Tissue, Hemangioma 1 (2%)
Subcutaneous Tissue, Hemangiosarcoma 1 (2%)
Subcutaneous Tissue, Histiocytic Sarcoma 1 (2%)
Subcutaneous Tissue, Lipoma 1 (2%)
Subcutaneous Tissue, Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
Page 11
NTP Experiment-Test: 90004-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC PROPYLENE GLYCOL MONO-T-BUTYL ETHER Date: 01/02/02
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 09:24:21
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 75 PPM 300 PPM 1200 PPM
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
None
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
None
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50) (50) (50)
Alveolar/Bronchiolar Adenoma 13 (26%) 7 (14%) 7 (14%)
Alveolar/Bronchiolar Carcinoma 6 (12%) 3 (6%) 4 (8%)
Alveolar/Bronchiolar Carcinoma, Multiple 1 (2%)
Carcinoma, Metastatic, Harderian Gland 1 (2%)
Carcinoma, Metastatic, Intestine Small,
Jejunum 1 (2%)
Hepatoblastoma, Metastatic, Liver 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 3 (6%) 2 (4%) 5 (10%) 3 (6%)
Histiocytic Sarcoma 1 (2%)
Osteosarcoma, Metastatic, Uncertain Primary
Site 1 (2%)
Plasma Cell Tumor Malignant, Metastatic,
Uncertain Primary Site 1 (2%)
Sarcoma, Metastatic, Mesentery 1 (2%)
Sarcoma, Metastatic, Skin 1 (2%)
Bronchiole, Adenoma 1 (2%)
Pleura (1) (1)
Osteosarcoma, Metastatic, Uncertain Primary
Site 1 (100%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (50) (50) (50) (50)
Adenoma 6 (12%) 4 (8%) 3 (6%) 4 (8%)
Carcinoma 1 (2%) 1 (2%) 2 (4%)
Bilateral, Adenoma 1 (2%)
____________________________________________________________________________________________________________________________________
Page 12
NTP Experiment-Test: 90004-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC PROPYLENE GLYCOL MONO-T-BUTYL ETHER Date: 01/02/02
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 09:24:21
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 75 PPM 300 PPM 1200 PPM
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (49) (50) (50)
Carcinoma, Metastatic, Intestine Small,
Jejunum 1 (2%)
Histiocytic Sarcoma 1 (2%)
Osteosarcoma, Metastatic, Uncertain Primary
Site 1 (2%)
Plasma Cell Tumor Malignant, Metastatic,
Uncertain Primary Site 1 (2%)
Renal Tubule, Adenoma 1 (2%)
Renal Tubule, Carcinoma 1 (2%)
Urinary Bladder (48) (48) (49) (50)
Transitional Epithelium, Papilloma 1 (2%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50) *(50)
Histiocytic Sarcoma 1 (2%)
Lymphoma Malignant 3 (6%) 1 (2%) 6 (12%) 3 (6%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 13
NTP Experiment-Test: 90004-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC PROPYLENE GLYCOL MONO-T-BUTYL ETHER Date: 01/02/02
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 09:24:21
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 75 PPM 300 PPM 1200 PPM
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 40 38 41 43
Total Primary Neoplasms 75 65 70 81
Total Animals with Benign Neoplasms 30 28 30 39
Total Benign Neoplasms 49 39 39 54
Total Animals with Malignant Neoplasms 20 20 26 18
Total Malignant Neoplasms 26 26 31 27
Total Animals with Metastatic Neoplasms 6 3 7 4
Total Metastatic Neoplasm 33 3 17 4
Total Animals with Malignant Neoplasms 2
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 14
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------